| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 134,224 | 121,984 | 114,802 | 119,839 |
| Cost of product revenue | 58,598 | 54,757 | 53,705 | 60,180 |
| Gross profit | 75,626 | 67,227 | 61,097 | 59,659 |
| Research and development | 1,528 | 1,031 | 826 | 412 |
| Plasma center operating expenses | 1,272 | 1,152 | 1,286 | 1,021 |
| Amortization of intangible assets | 38 | 32 | 25 | 28 |
| Selling, general and administrative | 21,776 | 22,214 | 24,079 | 18,560 |
| Total operating expenses | 24,614 | 24,429 | 26,216 | 20,021 |
| Income from operations | 51,012 | 42,798 | 34,881 | 39,638 |
| Interest income | 376 | 400 | 608 | 666 |
| Interest expense | 1,675 | 1,834 | 1,975 | 3,499 |
| Loss on extinguishment of debt | -2,177 | -1,159 | - | - |
| Other expense | -21 | -108 | -64 | -56 |
| Other expense, net | -3,497 | -2,701 | -1,431 | -2,889 |
| Income before income taxes | 47,515 | 40,097 | 33,450 | 36,749 |
| Provision for income taxes | 11,087 | 5,878 | 6,546 | 840 |
| Net income | 36,428 | 34,219 | 26,904 | 35,909 |
| Basic (in shares) | 238,602,978 | 241,490,715 | 237,775,476 | 234,571,376 |
| Basic earnings per common share (in dollars per share) | 0.15 | 0.14 | 0.11 | 0.15 |
| Diluted (in shares) | 244,664,263 | 248,608,460 | 244,676,350 | 244,804,065 |
| Diluted earnings per common share (in dollars per share) | 0.15 | 0.14 | 0.11 | 0.15 |
ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA)